ReviewTranslational psychiatry2023
Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis.
Review in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Elucidating the bidirectional association between autoimmune diseases and depression: a systematic review and meta-analysis.BMJ mental health · 2024Pooled it
- Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis.Journal of neurology · 2026Trial
- Dietary regimens and cognitive function in multiple sclerosis: a systematic review.Brain, behavior, & immunity - health · 2026Review
- Type-I IFNs in EAE drive synaptic transcriptional responses in neurons and astrocytes in the brain.bioRxiv : the preprint server for biology · 2026Article
- Preservation of positive emotion recognition in patients with multiple sclerosis: Artefact related to methodological issues or real feature of the disorder?Journal of neuropsychology · 2026Article
- Family stress model pathways to cognitive function in older adulthood.Journal of family psychology : JFP : journal of the Division of Family Psychology of the American Psychological Association (Division 43) · 2026Article
- Impact of Hatha Yoga on Cognitive Performance, Fatigue and Psychological Well-Being in Patients with Multiple Sclerosis.Healthcare (Basel, Switzerland) · 2026Article
- Genetic evidence for a causal role of depression in late-onset Alzheimer disease: A Mendelian randomization study.Medicine · 2026Article
- Iron accumulation in the corpus callosum: a quantitative MRI study in relapsing-remitting multiple sclerosis.Irish journal of medical science · 2026Article
- Article
- MRI Correlates of Depression and Anxiety in Multiple Sclerosis.Diseases (Basel, Switzerland) · 2026Review
- Rethinking prognosis in multiple sclerosis: a multiaxial perspective.Nature reviews. Neurology · 2026Review
- The role of health literacy in medication adherence among people living with multiple sclerosis: a cross-sectional study in Isfahan, Iran.BMC neurology · 2026Article
- Dynamic Triangulation of Resting-State Networks and CSF Metabolites Reveals Bidirectional Causal Pathways in Multiple Sclerosis: A Mendelian Randomization Analysis.Journal of molecular neuroscience : MN · 2026Article
- Temporal Association Between Reported Use of Psychoactive Substances and Cognitive Function in Individuals With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2026Article
- Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.Journal of neurology · 2026Article
- Lesion Location and Functional Connections Reveal Cognitive Impairment Networks in Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Psychological Burden in Relapsing-Remitting Multiple Sclerosis: Sociodemographic and Clinical Determinants of Persistent Anxiety and Depression over a Six-Month Follow-Up.Nursing reports (Pavia, Italy) · 2026Article
- Association between anxiety, depression, and fatigue in elderly patients with Parkinson's disease.World journal of psychiatry · 2026Article
- Cumulative burden of depression and domain-specific cognitive impairment over time in the women's interagency HIV study: A marginal structural model approach.Journal of affective disorders · 2026Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric abnormalities may be broadly divided in two categories: disorders of mood, affect, and behavior and abnormalities affecting cognition. Among these conditions, clinical depression, anxiety and neurocognitive disorders are the most common in multiple sclerosis (MS), with a substantial impact on patients' quality of life and adherence to treatments. Such manifestations may occur from the earliest phases of the disease but become more frequent in MS patients with a progressive disease course and more severe clinical disability. Although the pathogenesis of these neuropsychiatric manifestations has not been fully defined yet, brain structural and functional abnormalities, consistently observed with magnetic resonance imaging (MRI), together with genetic and immunologic factors, have been suggested to be key players. Even though the detrimental clinical impact of such manifestations in MS patients is a matter of crucial importance, at present, they are often overlooked in the clinical setting. Moreover, the efficacy of pharmacologic and non-pharmacologic approaches for their amelioration has been poorly investigated, with the majority of studies showing marginal or no beneficial effect of different therapeutic approaches, possibly due to the presence of multiple and heterogeneous underlying pathological mechanisms and intrinsic methodological limitations. A better evaluation of these manifestations in the clinical setting and improvements in the understanding of their pathophysiology may offer the potential to develop tools for differentiating these mechanisms in individual patients and ultimately provide a principled basis for treatment selection. This review provides an updated overview regarding the pathophysiology of the most common neuropsychiatric symptoms in MS, the clinical and MRI characteristics that have been associated with mood disorders (i.e., depression and anxiety) and cognitive impairment, and the treatment approaches currently available or under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.